JP2003516967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003516967A5 JP2003516967A5 JP2001544683A JP2001544683A JP2003516967A5 JP 2003516967 A5 JP2003516967 A5 JP 2003516967A5 JP 2001544683 A JP2001544683 A JP 2001544683A JP 2001544683 A JP2001544683 A JP 2001544683A JP 2003516967 A5 JP2003516967 A5 JP 2003516967A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound
- formulation
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- 235000010290 biphenyl Nutrition 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 description 3
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000005129 aryl carbonyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- -1 cyano, hydroxy Chemical group 0.000 description 3
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- HJMZMZRCABDKKV-UHFFFAOYSA-N carbonocyanidic acid Chemical group OC(=O)C#N HJMZMZRCABDKKV-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17113999P | 1999-12-16 | 1999-12-16 | |
| US60/171,139 | 1999-12-16 | ||
| PCT/US2000/034504 WO2001044193A1 (en) | 1999-12-16 | 2000-12-18 | 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003516967A JP2003516967A (ja) | 2003-05-20 |
| JP2003516967A5 true JP2003516967A5 (enExample) | 2008-02-21 |
Family
ID=22622694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001544683A Pending JP2003516967A (ja) | 1999-12-16 | 2000-12-18 | １，３，４−置換ピペリジン類似体および嗜癖の治療におけるそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20020025967A1 (enExample) |
| EP (1) | EP1248770A1 (enExample) |
| JP (1) | JP2003516967A (enExample) |
| CA (1) | CA2395075A1 (enExample) |
| WO (1) | WO2001044193A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| BRPI0412263B1 (pt) | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição |
| CN101163676A (zh) | 2005-02-23 | 2008-04-16 | 普雷萨药品公司 | 用于治疗运动障碍及其它cns适应症的多巴胺转运蛋白抑制剂 |
| AU2006216651A1 (en) * | 2005-02-23 | 2006-08-31 | Prexa Pharmaceuticals, Inc. | Multimediator dopamine transport inhibitors, and uses related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| EP2190844B3 (en) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| CA2741731A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
| US9452990B2 (en) | 2012-06-20 | 2016-09-27 | Novartis Ag | Complement pathway modulators and uses thereof |
| EP3174864A4 (en) * | 2014-07-31 | 2018-02-14 | Oregon Health & Science University | Vmat inhibitory compounds |
| US10000477B2 (en) | 2014-10-31 | 2018-06-19 | Indivior Uk Limited | Dopamine D3 receptor antagonist compounds |
| EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
| EP3322415A4 (en) | 2015-07-15 | 2019-03-13 | Axovant Sciences GmbH | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1058058B (de) * | 1954-02-27 | 1959-05-27 | Basf Ag | Verfahren zur Herstellung von Alkylpyridinen |
| GB850417A (en) * | 1957-05-31 | 1960-10-05 | Merck & Co Inc | Process for the preparation of 1-(p-nitrophenyl)-4-carboalkoxy-4-phenyl-piperidines |
| US4443451A (en) * | 1981-07-15 | 1984-04-17 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidin-5-one derivatives |
| DE3441927A1 (de) * | 1984-11-16 | 1986-05-28 | Basf Ag, 6700 Ludwigshafen | Am stickstoff substituierte 4-(p-tert.butyl-phenyl)-3-methyl-piperidine, dessen quartaere salze sowie deren anwendung als fungizide |
| US5620993A (en) * | 1995-06-07 | 1997-04-15 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| DK0975595T3 (da) * | 1997-04-07 | 2009-10-19 | Univ Georgetown | Kokainanaloger |
| EP1119553A1 (en) * | 1998-10-07 | 2001-08-01 | Georgetown University | Monomeric and dimeric heterocycles, and therapeutic uses thereof |
-
2000
- 2000-12-18 US US09/739,184 patent/US20020025967A1/en not_active Abandoned
- 2000-12-18 WO PCT/US2000/034504 patent/WO2001044193A1/en not_active Ceased
- 2000-12-18 EP EP00989325A patent/EP1248770A1/en not_active Withdrawn
- 2000-12-18 CA CA002395075A patent/CA2395075A1/en not_active Abandoned
- 2000-12-18 JP JP2001544683A patent/JP2003516967A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516967A5 (enExample) | ||
| JP2950597B2 (ja) | 硬膜外もしくは髄腔内局所投与用鎮痛剤 | |
| DE60026855T2 (de) | Synergistische kombination von roflumilast und salmeterol | |
| BRPI0115910B8 (pt) | medicamento compreendendo 5-[(r)-2-(5,6-dietil-indan-2ilamino)-1-hidróxi-etil]-8-hidróxi-1h-quinolin-2-ona e corticóides para o tratamento de doencas inflamatórias ou obstrutivas das vias aéreas | |
| CA2584524A1 (en) | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women | |
| WO2005102342A1 (en) | New pharmaceutical compositions for the treatment of sexual disorders ii | |
| RU2264401C3 (ru) | Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения и промежуточные вещества | |
| JP2008509187A5 (enExample) | ||
| JP2022188052A (ja) | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| RU2008146383A (ru) | ДИАЛКИЛФЕНИЛЬНЫЕ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МУСКАРИНОВЫХ РЕЦЕПТОРОВ | |
| US8729073B2 (en) | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | |
| JP2011507879A5 (enExample) | ||
| JP2005525364A5 (enExample) | ||
| JP2003501469A5 (enExample) | ||
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| RU2208013C2 (ru) | ПРОИЗВОДНЫЕ 8-ЗАМЕЩЕННОГО-9H-1,3-ДИОКСОЛ/4,5-h//2,3/БЕНЗОДИАЗЕПИНА, ЯВЛЯЮЩИЕСЯ ИНГИБИТОРАМИ AMPA/КАИНАТНОГО РЕЦЕПТОРА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ | |
| JPH02138214A (ja) | 不安を治療する方法 | |
| JP2005516035A5 (enExample) | ||
| US6403589B1 (en) | Method of treating pain with draflazine-analogues | |
| ATE410168T1 (de) | A1 adenosin-rezeptor-antagonisten | |
| US5434177A (en) | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | |
| JP2002536442A5 (enExample) | ||
| US5536749A (en) | Method for attenuation of sympathetic nervous system activity or onset of migraine by selectively metabolized beta-blocking agents | |
| CA2307028A1 (en) | Medicinal uses of phenylalkanols and derivatives |